ALDH1A2 and cancer: These data identify ALDH1A3 (and potentially ALDH1A2) as a potential target to inhibit retinoid nuclear receptor-mediated immune suppression in cancers, thus offering an orthogonal approach to immune checkpoint blockade in cancer immunotherapy.